article thumbnail

FDA approves label updates for BMS’ CAR T cell therapies

Pharmaceutical Technology

Last month, European Commission approved the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) with a dosage strength of 600 mg/vial, expanding treatment options for various adult solid tumours. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

article thumbnail

First patient dosed in trial for novel dry AMD treatment PST-611

Pharma Times

Once safety and dosage are confirmed, the company plans to begin a phase 2a proof-of-concept study. Content News Magazine Advertise Contact Competitions Connect Follow Follow Follow Follow Follow Legal Privacy Policy Terms and Conditions Editorial policy Cookies RSS – feed subscriptions © Copyright PharmaTimes Media Limited 2023

Dosage 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pipelinepharma marketplace records quadruple growth over a single year

Pharma Mirror

The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. New finished dosage form categories for medical devices and nutraceuticals will also be launched in the coming months. While quantity is sometimes a quality in itself, our product listings are curated by.

Dosage 52
article thumbnail

BENEO presents galenIQ for highly flowable and stable sachet powders

Pharma Mirror

To ensure accurate dosage and administration, the powders used in these delivery systems require excellent flowability. BENEO’s filler-binder galenIQ™ 721 meets this demand and helps formulators to develop more convenient dosage forms. Consumers appreciate their ease of use and the ability to take them without water.

Dosage 52
article thumbnail

BENEO’s galenIQ™ 721 filler-binder optimizes the production of fizzy tablets and powders

Pharma Mirror

Effervescent dosage forms offer distinct advantages compared with traditional tablets. The post BENEO’s galenIQ™ 721 filler-binder optimizes the production of fizzy tablets and powders appeared first on Pharma Mirror Magazine. Forinstance, many patients have problems swallowing tablets. In addition, they can be usedto formulate.

Dosage 40
article thumbnail

Innovative Healthcare Advertising Strategies: Transforming Pharma Marketing in the Digital Era

Pharma Marketing Network

Television and Print: While digital is dominant, TV and magazines still play a role, especially for older audiences. Instagram for Patients: Use visuals to simplify complex topics, like dosage instructions or potential side effects. AI-Powered Insights Artificial Intelligence can refine advertising strategies.

Dosage 52
article thumbnail

How to conduct GMP training for employee

GMPSOP

Product Overview: – Controlled drugs – Dosage forms – GMP – Applicable regulations – Introduction to the FDA c. Facility Overview: – General layout of the facility – Flow of materials and people – Controlled access areas – Departmental organisation b.